Aglaia Therapeutics Raises €4M in Seed Funding

Aglaia Therapeutics, a Villejuif, France-based biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, closed a €4M ($4.7M) seed funding round.

The round was led by Advent France Biotechnology (AFB) with participation from Crédit Mutuel Innovation and Pierre Fabre.

The proceeds of the funding will be used to prepare the preclinical development program required to identify the first candidate. Aglaia Tx aims to develop promising new oncology therapies with the goal of delivering drugs that can restore sensitivity to current targeted therapies in cancer patients that became resistant to these treatments. The company established a pipeline of small molecules in oncology targeting the initiation of mRNA translation. 

Aglaia Therapeutics is a biotechnology startup developing promising new oncology therapies. The company aims at delivering drugs that restore sensitivity to current targeted therapies in cancer patients that have become resistant to these treatments. Aglaia Therapeutics has established a pipeline of small molecules, targeting the initiation of mRNA translation, which the company acquired and developed through Pierre Fabre. 

AFB also acted as co-founder, with Alejo Chorny, current operating partner at AFB, now appointed chief operating officer (COO) of Aglaia Tx. Leading European cancer centers Institut Curie and Gustave Roussy participated in the creation of the company. 

A collaboration between Aglaia Therapeutics, Gustave Roussy, Institut Curie and the University of Strasbourg, for the validation of targets involved in certain types of cancer, will allow the startup to keep working with the research and clinical teams of Pr Caroline Robert, Dr Stéphan Vagner and Dr Laurent Desaubry.

Aglaia Tx is founded on the basis of years of collaborative scientific work performed by Pr Caroline Robert, head of the dermatology department at Gustave Roussy Cancer Campus (France), Dr Stéphan Vagner, head of the CNRS UMR3348 / Inserm U1278 Unit at Institut Curie (France) and Dr Laurent Desaubry, CNRS research director at the University of Strasbourg (France) who are co-founders of the startup.